Cost-effectiveness analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for the prevention of RSV illness among infants in Hong Kong
Year-round RSVpreF maternal vaccination would substantially reduce RSV's clinical and economic burden among infants in Hong Kong and would be a cost-effective program.
Authors
- Luka Ivkovic
- Robyn Kendall (ORCID: https://orcid.org/0000-0001-6331-5497)
- Victoria D. Wong
- Michael Fung
- Amy W. Law
- Diana Mendes
Institutions
- Department of Health (CN)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Centre for Advancing Health Outcomes (CA)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.ijid.2026.108503
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00